Davide Ruggero

Davide Ruggero

Auto-generated profile, based on publicly available information

Davide Ruggero

Department of Urology, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2012 in Nature
Verified
Journal Article
Open access
PDF file
AHAndrew C. Hsieh
Andrew C. Hsieh
YLYi Liu
Yi Liu
MEMerritt P. Edlind
Merritt P. Edlind
NINicholas T. Ingolia
Nicholas T. Ingolia
MJMatthew R. Janes
Matthew R. Janes
DRDavide Ruggero
Davide Ruggero
The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein synthesis that couples nutrient sensing to cell growth and cancer. However, the downstream translationally regulated nodes of gene expression that may direct cancer development are poorly characterized. Using ribosome profiling, we uncover specialized translation of the prostate cancer genome by oncogenic mTOR signalling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metabolism and invasion. We extend these findings by functionally characterizing a class of translationally controlled pro-invasion messenger RNAs that we show direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signalling. Furthermore, we develop a clinically relevant ATP site inhibitor of mTOR, INK128, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure. Together, these findings extend our understanding of how the ‘cancerous’ translation machinery steers specific cancer cell behaviours, including metastasis, and may be therapeutically targeted.

1 March 2010 in Cancer Cell
Verified
Journal Article
Closed access
AHAndrew C. Hsieh
Andrew C. Hsieh
MCMaria Costa
Maria Costa
OZOrnella Zollo
Ornella Zollo
CDCole Davis
Cole Davis
MFMorris E. Feldman
Morris E. Feldman
DRDavide Ruggero
Davide Ruggero

16 November 2008 in Nature
Verified
Journal Article
Open access
PDF file
MBMaria Barna
Maria Barna
APAya Pusic
Aya Pusic
OZOrnella Zollo
Ornella Zollo
MCMaria Costa
Maria Costa
NKNadya Kondrashov
Nadya Kondrashov
DRDavide Ruggero
Davide Ruggero
Barna et al. show that Myc-driven tumorigenesis is dependent on its ability to increase protein synthesis, as haploinsufficiency in ribosomal proteins decreases Myc-induced tumour formation. However, tumours caused by the loss of p53 were not affected. Myc stimulates cap-dependent protein translation at the expense of IRES-dependent translation, leading to the synthesis of a different set of proteins, and this effect is reversed by ribosomal protein haploinsufficiency. Of the proteins misregulated, Cdk11 is shown to be important for the effects of Myc on genomic instability that probably contributes to Myc-induced tumour formation. This study shows that Myc-driven tumourigenesis is dependent on its ability to increase protein synthesis, as haploinsufficiency in ribosomal proteins decreases Myc-induced tumour formation. However, tumours caused by the loss of p53, were not affected. Myc stimulates cap-dependent protein translation at the expense of IRES-dependent translation, leading to the synthesis of a different set of proteins, and this effect is reversed by ribosomal protein haploinsufficiency. The Myc oncogene regulates the expression of several components of the protein synthetic machinery, including ribosomal proteins, initiation factors of translation, RNA polymerase III and ribosomal DNA1,2. Whether and how increasing the cellular protein synthesis capacity affects the multistep process leading to cancer remains to be addressed. Here we use ribosomal protein heterozygote mice as a genetic tool to restore increased protein synthesis in Eμ-Myc/+ transgenic mice to normal levels, and show that the oncogenic potential of Myc in this context is suppressed. Our findings demonstrate that the ability of Myc to increase protein synthesis directly augments cell size and is sufficient to accelerate cell cycle progression independently of known cell cycle targets transcriptionally regulated by Myc. In addition, when protein synthesis is restored to normal levels, Myc-overexpressing precancerous cells are more efficiently eliminated by programmed cell death. Our findings reveal a new mechanism that links increases in general protein synthesis rates downstream of an oncogenic signal to a specific molecular impairment in the modality of translation initiation used to regulate the expression of selective messenger RNAs. We show that an aberrant increase in cap-dependent translation downstream of Myc hyperactivation specifically impairs the translational switch to internal ribosomal entry site (IRES)-dependent translation that is required for accurate mitotic progression. Failure of this translational switch results in reduced mitotic-specific expression of the endogenous IRES-dependent form of Cdk11 (also known as Cdc2l and PITSLRE)3,4,5, which leads to cytokinesis defects and is associated with increased centrosome numbers and genome instability in Eμ-Myc/+ mice. When accurate translational control is re-established in Eμ-Myc/+ mice, genome instability is suppressed. Our findings demonstrate how perturbations in translational control provide a highly specific outcome for gene expression, genome stability and cancer initiation that have important implications for understanding the molecular mechanism of cancer formation at the post-genomic level.

26 April 2016 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
MTMorgan L. Truitt
Morgan L. Truitt
DRDavide Ruggero
Davide Ruggero

1 July 2015 in Cell
Verified
Journal Article
Closed access
MTMorgan L. Truitt
Morgan L. Truitt
CCCrystal S. Conn
Crystal S. Conn
ZSZhen Shi
Zhen Shi
XPXiaming Pang
Xiaming Pang
TTTaku Tokuyasu
Taku Tokuyasu
DRDavide Ruggero
Davide Ruggero

5 July 2012 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
DRDavide Ruggero
Davide Ruggero
The link between perturbations in translational control and cancer etiology is becoming a primary focus in cancer research. It has now been established that genetic alterations in several components of the translational apparatus underlie spontaneous cancers as well as an entire class of inherited syndromes known as “ribosomopathies” associated with increased cancer susceptibility. These discoveries have illuminated the importance of deregulations in translational control to very specific cellular processes that contribute to cancer etiology. In addition, a growing body of evidence supports the view that deregulation of translational control is a common mechanism by which diverse oncogenic pathways promote cellular transformation and tumor development. Indeed, activation of these key oncogenic pathways induces rapid and dramatic translational reprogramming both by increasing overall protein synthesis and by modulating specific mRNA networks. These translational changes promote cellular transformation, impacting almost every phase of tumor development. This paradigm represents a new frontier in the multihit model of cancer formation and offers significant promise for innovative cancer therapies. Current research, in conjunction with cutting edge technologies, will further enable us to explore novel mechanisms of translational control, functionally identify translationally controlled mRNA groups, and unravel their impact on cellular transformation and tumorigenesis.